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Summary Tumour markers CEA, CA-195 and CA-242 were measured in 33 patients undergoing
chemotherapy for advanced colorectal cancer. The aim was to determine whether they could be used to
accurately monitor the course of the disease, and reduce the need for imaging. Treatment with a 5-fluorouracil
based regimen resulted in a partial response in nine patients (27%), whereas the remainder either had disease
stabilisation or suffered from progression. Before treatment the CEA was elevated in 85% of patients and the
CA-195 and CA-242 in 78%. All three markers were elevated in 70% and at least one elevated in 93%.
CA-195 and CA-242 appeared to be co-expressed, by contrast with the CEA. When compared to the results of
serial CT scanning the CEA correlated best with the course of the disease, the positive predictive value being
54% for a partial response, 77% for minor and partial responses combined and 100% for progressive disease.
The corresponding values for CA-195 were 46%, 62% and 100% respectively and for CA-242, 50%, 67% and
100% respectively. Thus, although falling levels of markers overestimate the number of responses demon-
strated by imaging, rising tumour markers invariably herald progressive disease. This was often evident up to
16 weeks before progression was observed on scanning. CEA is the most useful of the three markers in the
monitoring of patients being treated for advanced colorectal cancer, but other markers may prove valuable if
the CEA is normal. The use of tumour markers should reduce the need for regular scanning.
Although the outlook for patients with advanced colorectal
cancer has traditionally been poor, recent advances have
improved this situation. Treatment with a combination of
5-fluorouracil (5-FU) and leucovorin has been shown to
result in an objective response in approximately 30 to 40% of
patients with proven survival benefit (Poon et al., 1989;
Petrelli et al., 1989). Similar, or higher, response rates, in-
cluding some complete responses, are now also being
reported in patients treated with 5-FU in combination with
interferon-alpha (Wadler et al., 1989; Wadler & Wiernik,
1990). The response to systemic chemotherapy is usually
assessed by serial imaging, commonly in the form of CT
scanning. Evaluation by this means is, however, expensive
and time consuming for the patient. The purpose of
evaluating patients response include the early identification of
non-responders, who may then be spared further treatment
with associated toxicity, as well as the evaluation of maximal
responses which may also allow treatment discontinuation
with some regimens. Simple and inexpensive tests may be
repeated frequently to allow more precise use of regimens
and, potentially, improve patient care.
A number of tumour markers have been demonstrated to
be elevated in patients with colorectal cancer. Carcino-
embryonic antigen (CEA) is the best known and most widely
used of the markers (Minton et al., 1985; Staab et al., 1985;
Wanebo et al., 1989), but in recent years the production of
monoclonal antibodies against colorectal cancer-associated
mucin antigens have allowed the detection of a further series
of markers. These include CA 19-9, CA-50, CA-195 and
CA-242 (Hammarstrom, 1985; Gupta et al., 1987; Safi et al.,
1987; Sagar et al., 1991; Nilsson et al., 1992). Although none
of these markers has proved to be of any particular value in
screening for the disease, CEA is commonly used to assess
the progress of patients following surgical treatment (Minton
et al., 1985) and remains the 'gold standard'. Other markers
appear less useful in isolation, but when combined as a panel
with CEA may be of greater value than any one marker on
its own (Safi et al., 1987; Persson et al., 1989). The aim of
this study was to assess whether three tumour markers CEA,
CA-195 and CA-242 are of value in monitoring the progress
of patients being treated with systemic chemotherapy for
advanced colorectal cancer.
Patients and methods
Patients
Thirty-three patients were studied; 24 were male and nine
female, mean ages 58 (range 27-76) and 60 (42-78) respec-
tively. All patients had histologically proven colorectal cancer
with metastases. Twenty-six had liver metastases, ten
locoregional disease, eight lung metastases, and two with
disease at other sites. Several of these patients had disease at
more than one site. The patients were a consecutive series in
chemotherapy studies which required that the disease was
measurable on CT scan. The time interval between presenta-
tion with the primary tumour and recurrent disease averaged
at 16 months with a range of 0-91 months. Performance
status was assessed by means of the Karnofsky scale (Kar-
nofsky et al., 1948), the average being 80 with a range of
70-90.
The study was approved by Leeds Eastern District Clinical
Research (Ethics) Committee.
Treatment schedule
All patients received chemotherapy with a 5-fluorouracil (5-
FU) based regimen as detailed below. Some of these patients
were being treated in a multi-centre study comparing 5-FU
and interferon alpha with 5-FU and leucovorin. The results
of this study will be published separately. In the 5-FU/
interferon based regimen 5-FU was administered as a con-
tinuous intravenous infusion over a period of 5 days at a
daily dose of 750 mgm2 followed by weekly intravenous
bolus doses also of 750 mg m-2 commencing on day fifteen.
Interferon alpha-2a 9 MU, was administered as a sub-
cutaneous injection three times weekly. In the 5-FU/
leucovorin based regimen I-leucovorin 200 mg m-2 was
infused over 10 min and followed within 5 min by a bolus of
5-FU at 370 mg m-2 for 5 consecutive days. This cycle was
repeated every 4 weeks.
Tumour markers
A 10 ml sample of venous blood was obtained at baseline
and at monthly intervals thereafter for tumour marker assess-
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ment. The plasma was immediately separated and frozen at
- 20°C until assayed. CEA and CA-195 (Hybri C-mark)
were measured by a solid phase (TandemTm) two site
immunoradiometric assay using commercial kits (Hybritech,
Liege, Belgium). CA-242 was measured by a DELFIATM
assay obtained from Wallac Oy, Turku, Finland. The normal
range for CEA was 0-5ngml-', CA-195 0-12Uml' and
CA-242 0-20 U ml-'. The coefficient of variation for the
CEA was <5.9% within assay (20 replicates) and <7.2%
between (44 batches), for the CA-195, <6.4% within assay
(20 replicates) and < 7.9% between (ten batches) and for the
CA-242, <7% within assay (20 replicates) and <8.5%
between (ten batches). These values applied over the whole of
the concentration ranges of the three assays. A rise or fall in
a tumour marker was defined as a greater than 15% increase
or decrease in the marker on at least two occasions 1 month
apart. For the purposes of this study such an increase was
considered to be 'positive' as regards the detection of pro-
gressive disease and such a decrease considered to be
'positive' in the assessment of a response to treatment (com-
plete, partial or minor, see below).
Tumour assessments
CT scanning was performed in the 2 weeks before treatment
started, and at 8 weekly intervals thereafter to assess re-
sponse to treatment. Tumour response was graded in accor-
dance with WHO criteria as described in WHO Handbook
for Reporting Results of Cancer Treatments (1979). On the
basis of the results from the CT scans and clinical outcome,
the patients course was divided into 'patient events' which
corresponded to WHO response criteria, and changes in
marker expression were compared to serial CT scanning
during these events. Comparison of changes in tumour
markers to CT in patients undergoing an objective response
or suffering from progressive disease were expressed in terms
of sensitivity, specificity and positive and negative predictive
value.
The following definitions apply:
Sensitivity: True positive/(True positive + false negative)
x 100%.
Specificity: True negative/(True negative + false positive)
x 100%.
Positive predictive value: True positive/(True positive +
false positive) x 100%.
Negative predictive value: True negative/(True negative
+ false negative) x 100%.
Statistical methods
Non-parametric statistical methods were used throughout as
the data were markedly skewed. Comparisons between
unpaired groups were made using the Mann-Whitney U-test
and correlation assessed using the Spearman rank order cor-
relation (Cohen & Holliday, 1982).
Results
Thirty-three evaluable patients were available for study,
although in six only the CEA was measured before treatment
commenced. Over the course of the patients' treatment there
were nine patient episodes in which the disease partially
responded to therapy, 24 episodes of disease stabilisation and
24 episodes of progressive disease. It was clear that in
patients with progressive disease a rise in a marker level often
preceded by several months deterioration observed on the CT
scan. For this reason a- rising marker level was regarded as
being a true positive if either of the two subsequent CT scans
revealed progression. Similarly, some patients with falling
marker levels clearly had tumour shrinkage on scanning
which did not fulfil the criteria of a partial response. For this
reason the data for partial responses and for minor and
partial responses combined are presented separately.
All three markers were measured at baseline in 27 patients
and they were all elevated in 19 (70%) of these patients. The
CEA was elevated in 23 (85%) and CA-195 and CA-242
were elevated in 21 (78%). In four patients the CEA alone
was elevated and in three patients the CA-195 and CA-242
were elevated in the absence of an elevated CEA. In one
patient CA-242 alone was elevated. Thus, in 25 of the 27
patients (93%) at least one marker was elevated. Considering
the patients in whom the markers were elevated, the median
(quartiles) level of the CEA was 45 (14-353) ng ml-', the
CA-195 433 (16-1370)Uml-' and the CA-242 389 (123-
2401) U ml-'. There was no correlation between the presence
of an elevated marker and the site of metastatic disease.
Throughout the study there was an excellent correlation
between the levels of CA-195 and CA-242 (Spearman rho
0.97, P<0.0001). There was, however, a much poorer cor-
relation between the CEA and the CA-195 (Spearman rho
0.64, P<0.001) or the CA-242 (Spearman rho 0.61,
P< 0.005).
Comparisons between the trend in the markers (where
those markers were elevated at the start of the period being
considered) and the CT findings are shown in Tables I to III.
A fall in any of the markers was highly sensitive in the
prediction of a partial response on CT (100% for all three
markers) but the specificity was lower resulting in a positive
predictive value of 54% for a fall in CEA, 46% for a fall in
CA-195 and 50% for a fall in CA-242. The negative predic-
tive value for partial response was 100% for all three
markers (Table I). When consideration was given to all
patients who demonstrated any degree of tumour shrinkage
on treatment then the specificity improved, resulting in
positive predictive values of 77%, 62% and 67% for CEA,
CA-195 and CA-242 respectively (Table II). The sensitivity
Table I The sensitivity, specificity and positive and negative predictive
values, expressed as a percentage (in parenthesis), of serial tumour
marker measurements in evaluating a partial response as demonstrated
by CT scanning. The absolute numbers from which the percentages are
derived are also shown
CEA CA-195 CA-242
Sensitivity (%) 7/7 (100) 6/6 (100) 6/6 (100)
Specificity (%) 11/17 (65) 6/13 (46) 6/11 (54)
Positive predictive 7/14 (54) 6/13 (46) 6/12 (50)
value (%)
Negative predictive 11/11 (100) 6/6 (100) 7/7 (100)
value (%)
Table II The sensitivity, specificity and positive and negative
predictive values, expressed as a percentage (in parenthesis), of serial
tumour marker measurements in evaluating both minor and partial
responses as demonstrated by CT scanning. The absolute numbers from
which the percentages are derived are also shown
CEA CA-195 CA-242
Sensitivity (%) 10/10 (100) 8/8 (100) 8/8 (100)
Specificity (%) 11/14 (79) 6/11 (55) 7/11 (64)
Positive predictive 10/13 (77) 8/13 (62) 8/12 (67)
value (%)
Negative predictive 11/11 (100) 6/6 (100) 7/7 (100)
value (%)
Table III The sensitivity, specificity and positive and negative
predictive values, expressed as a percentage (in parenthesis), of serial
tumour marker measurements in evaluating a progresssive disease as
demonstrated by CT scanning. The absolute numbers from which the
percentages are derived are also shown
CEA CA-195 CA-242
Sensitivity (%) 17/23 (74) 13/21 (62) 12/20 (60)
Specificity (%) 14/14 (100) 12/12 (100) 12/12 (100)
Positive predictive 17/17 (100) 13/13 (100) 13/13 (100)
value (%)
Negative predictive 14/20 (70) 12/18 (67) 12/20 (60)
value (%)
1134 U. WARD et al.
and negative predictive value were unchanged by the in-
clusion of minor responses. Considering the prediction of
progressive disease, the sensitivity of rising markers was 74%
for CEA and 62% and 60% for CA-195 and CA-242. The
specificity was 100% for all markers and the positive predic-
tive value was also 100%. The negative predictive value was
70%, 67% and 60% for CEA, CA-195 and CA-242 respec-
tively.
The performance of each marker was then evaluated by
comparison with the results of CT scanning over the whole
period of the patients treatment. On this basis, where the
CEA was elevated, the marker correlated with the disease
course in 88% of patients, was unhelpful in 4% and was
incorrect in 8%. The change in CA-195 correlated with
disease course in 70% of patients, was unhelpful in 9% and
incorrect in 21%. The change in CA-242 correlated with the
disease course in 65% of patients, was unhelpful in 13% and
incorrect in 22%.
Discussion
Treatment of advanced colorectal cancer with 5-FU in com-
bination with leucovorin or interferon is becoming widely
practised and, although the response rates are not good by
comparison with more chemosensitive malignancies, they are
much better than that achieved with 5-FU alone. The treat-
ment appears to be associated with survival benefit in com-
parative studies (Poon et al., 1989; Petrelli et al., 1989) and,
hence, the benefit may be very considerable in patients who
respond to treatment.
This study has established the role and limitations of three
colorectal cancer tumour markers in monitoring the course of
the disease. CEA, the most commonly used tumour marker,
appears to be the most useful in that it is elevated in excess
of 80% of the patients with advanced disease, and has the
best predictive value of the three markers studied. Where the
CEA was elevated no additional information was obtained
from measuring AC-195 and CA-242. However, these
markers were still of value in monitoring patients when the
baseline CEA was not elevated, and this is consistent with
the fact that they are expressed independently of CEA (Ham-
marstrom, 1985; Persson et al., 1989). At least one of the
three tumour markers was elevated in 97% of patients. CA-
195 and CA-242, however, tended to change in synchrony, as
indicated by the very good correlation between them, and
this suggests that they are not independently expressed. Cer-
tainly there was no benefit from measuring them both.
Whichever marker is used, it is clear that the limitation to
their use in isolation is the overestimation of the number of
patients who respond to treatment and underestimation of
the number suffering progressive disease as demonstrated on
CT. By contrast, a tumour response was never seen in the
absence of falling marker levels and, similarly, rising marker
levels invariably heralded tumour progression within 16
weeks. This early prediction of disease progression has been
noted previously (Persson et al., 1989). As regards the over-
estimation of responses, this is perhaps explicable on the
basis that the treatment was having a significant inhibitory
effect on the tumour which was insufficient to result in a
response on CT. This is supported by the fact that some of
the patients with falling markers had minor responses dem-
onstrated on CT. In addition, it has been demonstrated that
a fall in the CEA is associated with survival benefit even
when there is no reduction in tumour burden on scanning
(Allen-Mersh et al., 1987). This suggests that tumour markers
may actually be more sensitive in assessing tumour responses
than imaging. The lack of rising markers in patients with
progressive disease is a more serious limitation, but pre-
sumably reflects the growth of clones that do not express the
marker.
It is clear that tumour markers cannot replace the use of
imaging in the management and assessment of patients with
colorectal cancer. They are, however, sufficiently sensitive
and useful to be employed as the primary means of follow-
up, providing at least one marker is elevated, and scanning
techniques used to confirm the response suggested by the
change in marker expression. In addition, markers may be
used with some confidence in patients in whom the disease is
not easily evaluable, such as those with diffuse intra-
peritoneal metastases.
In conclusion, we would recommend that serial CEA
measurements are performed on all patients undergoing
chemotherapy for advanced colorectal cancer. Only if the
marker proves not to be elevated should an alternative such
as CA-195 or CA-242 be used. The appropriate marker can
be used as the primary means of monitoring treatment, and
imaging used to confirm the response. We estimate that such
a strategy may reduce by 50% the number of scans per-
formed on an individual patient.
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